Keywords
fibrinolytic activity
thromboelastograph
platelet aggregation
activated partial thromboplastin time
Full Text
Abstract
Introduction. Early in vitro studies anticoagulant and fibrinolytic effects of arginine-containing glyprolins on plasma in rats were revealed.
Aim: to study the effects of arginine-containing glyprolines His-Phe-Arg-Trp-Pro-Gly-Pro (HFRWPGP), Thr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP), Arg-Glu-Arg-Pro-Gly-Pro (RERPGP) on rat’s hemostasis in vivo in normal conditions and to compare the effects of test peptides with glyproline (PGP).
Materials and methods. The following peptides were used: HFRWPGP (ACTH(6–9) PGP), TKPRPGP (Selank), RERPGP and PGP. In experiments, 20 white rats have intranasally injected with 0.02 ml of each peptide solution in a dose of 1 μg/kg body weight (3 experimental groups) or 0.85% NaCl solution (control group) every 24 hours for 7 days (168 hours). The effects of peptides on hemostatic parameters were investigated by thromboelastographic method, by activated partial thromboplastin time and platelet aggregation, also fibrinolytic blood activity on non-stabilized fibrin was determined.
Results. All tested peptides showed anticoagulant, fibrinolytic, antiplatelet activity. Anticoagulant effects manifested 20 hours after the last injection and persisted for 168 hours. Arginine-containing — Arg-Glu-Arg-Pro-Gly-Pro and Selank showed the greatest effect.
Conclusion. Arginine as a part of arginine-containing glyprolines intensified the activation of anticoagulation system.
REFERENCES
1. Pharmaceutical technology. Solid dosage forms: a textbook. [Farmacevticheskaya tekhnologiya. Tverdye lekarstvennye formy: uchebnoe posobie (Pod red. S.A. Kedika)]. Moskva: Institut farma- cevticheskih tekhnologij, 2011. 661 s (in Russ.).
2. Khavinson V. Kh., Kvetnaya Т.V. Regulatory peptides and homeo- stasis. [Regulyatornye peptidy i gomeostaz]. Rossijskij himicheskij zhurnal. 2005;49(1):112–7 (in Russ.).
3. Lebedko O.A., Timoshin S.S. The effect of regulatory peptides on the processes of DNA synthesis in different cell populations: the- oretical and applied aspects. [Vliyanie regulyatornyh peptidov na processy sinteza DNK v razlichnyh kletochnyh populyaciyah: teoreticheskie i prikladnye aspekty]. Dal’nevostochnyj medicinskij zhurnal. 2011;(2):6–11 (in Russ.).
4. Craik D.J., Fairlie D.P., Liras S., Price D. The future of peptide- based drugs. Chem Biol Drug Des. 2013;81(1):136–47.
5. Kamensky A.A., Sergeev I. Yu. Regulatory peptides: drugs are cre- ated, but less than expected. [Regulyatornye peptidy: lekarstva sozdayutsya, no men’she, chem ozhidalos’]. Priroda. 2015;(4):29– 35 (in Russ.).
6. Ashmarin I.P., Kamensky A.A., Lyapina L.A. et al. Gliprolins as independent regulators and stabilizers of other peptides. [Glipro- liny kak samostoyatel’nye regulyatory i stabilizatory drugih pep- tidov]. Voprosy biologicheskoj, medicinskoj i farmacevticheskoj hi- mii. 2002;1:24–7 (in Russ.).
7. Lyapina L.A., Pastorova V.E., Samonina G.E., Ashmarin I.P. The effect of prolil-glycil-proline (PGP) peptide and PGP-rich sub- stances on haemostatic parameters of rat blood. Blood Coagul Fi- brinolysis. 2000;11(5):409–14.
8. Cherkasova K.A., Lyapina L.A., Ashmarin I.P. Comparative study of modulatory effects of Semax and primary proline-con- taining peptides on hemostatic reactions. [Sravnitel’noe issledo- vanie dejstviya preparata semaks i prostejshih prolinsoderzhash- chih peptidov v modulyacii gemostaticheskih reakcij]. Byulleten’ eksperimental’noj biologii i mediciny. 2001;132(1):625–6 (in Russ.).
9. Ashmarin I.P., Lyapina L.A., Andreeva L.A. et al. Therapeutic effect of Pro-Gly and Pro-Gly-Pro glyiprolines in the development of experi- mental insulin-dependent diabetes. [Lechebnyj effekt gliprolinov Pro- Gly i Pro-Gly-Pro pri razvitii eksperimental’nogo insulinozavisimogo diabeta]. Tromboz, gemostaz i reologiya. 2008;(2):38–43 (in Russ.).
10. Zakutskiy A.N., Chalisova N.I., Subbotina T.F. Functional arginine- containing sequences in peptides and proteins. [Funkcional’nye argininsoderzhashchie posledovatel’nosti v peptidah i belkah]. Bioorganicheskaya himiya. 2008;34(2):149–59 (in Russ.).
11. Yang W., Chan V.C., Kirkpatrick A. et al. Gly-Pro-Arg confers sta- bility similar to Gly-Pro-Hyp in the collagen triple-helix of host-
guest peptides. J Biol Chem. 1999;272(46):28837–40.
12. Brunini T.M.C., Mendes-Ribeiro A.C., Ellory J.C., Mann G.E. Plate- let nitric oxide synthesis in uremia and malnutrition: a role for L-arginine supplementation in vascular protection? Cardiovasc Res. 2007;73:359–67.
13. Napoli C.C., Stanley W.C., Ignarro L.J. Nutrition and cardiovascular disease: Putting a pathogenetic framework into focus. Cardiovasc Res. 2007;73:253–6.
14. Barkagan Z.S., Momot A.P. Diagnosis and controlled therapy of hemostasis disorders. [Diagnostika i kontroliruemaya terapiya narushenij gemostaza]. Moskva: N’yudiamed, 2001. 296 s (in Russ.). 15. McConell G.K. Effects of L-arginine supplementation on exercise metabolism. Curr Opin Clin Nutr Metab Care. 2007;10(1):46–51. 16. Méndez J.D., Balderas F.L. Inhibition by l-arginine and spermi- dine of hemoglobin glycation and lipid peroxidation in rats with induced diabetes. Biomed Pharmacother. 2006;60(1):26–31.
17. Rogozinskaya E. Ya., Lyapina M.G. Anticoagulant effects of arginine-containing peptides of glyiproline series (His-Phe-Arg- Trp-Pro-Gly-Pro, Thr-Lys-Pro-Arg-Pro-Gly-Pro) according to the thromboelastographic study. [Protivosvertyvayushchie effekty argi- ninsoderzhashchih peptidov gliprolinovogo ryada (His-Phe-Arg- Trp-Pro-Gly-Pro, Thr-Lys-Pro-Arg-Pro-Gly-Pro) po dannym trom- boelastograficheskogo issledovaniya]. Byulleten’ eksperimental’noj biologii i mediciny. 2017;164(8):197–200 (in Russ.).
18. Lyapina L.A., Grigorieva M.E., Obergan T. Yu., Shubina T.A. The- oretical and practical questions of studying of functional state of blood anticoagulant system. [Teoreticheskie i prakticheskie voprosy izucheniya funkcional’nogo sostoyaniya protivosvertyvayushchej sistemy krovi]. Moskva: Advansed Solyushnz, 2012. 160 s (in Russ.). 19. Vasilijević A., Buzadžić B., Korać A. et al. Benefical effects of L-arginine-nitric oxide — producing pathway in rats treated with alloxan. J Physiol. 2007;584(3):921–33.